Gen-Probe→Hologic
Acquisition · Cash · HOLX · announced Apr 30, 2012
Announced
Apr 30, 2012
Closed
Aug 1, 2012
Economics
Cash()
Pre-deal · pre-deal mark: 2012, year precision · rounding grid ±$100M · Hologic 8-K filing, SEC EDGAR — Gen-Probe acquisition (NASDAQ:GPRO)
Aggregate ~$3.7B including assumption of debt; $82.75/share cash tender
Target
Gen-Probe
Diagnostics · Diagnostic / genomic
HQ San Diego, CA · Founded 1988
Leader in molecular diagnostics including HPV/cervical cancer testing and STI screening
- SEC EDGAR - Hologic 8-K/DEFM14A (2012)
- Hologic press release (August 1, 2012)
- Gen-Probe Incorporated SEC filings
Acquirer
Hologic (HOLX)
Breast Health
HQ Marlborough, MA
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Added molecular diagnostics leadership including Aptima HPV test and cervical cancer screening to Hologic's women's health portfolio
Evidence ladder
Primary (regulatory / filing)
SEC EDGAR DEFM14A filing
SEC EDGAR filings (ticker locator)Secondary (press / IR)
Hologic press release (August 1, 2012)
Limitations
- Aggregate ~$3.7B including assumption of debt; $82.75/share cash tender
- Pre-deal valuation sourced from: Hologic 8-K filing, SEC EDGAR — Gen-Probe acquisition (NASDAQ:GPRO). Pre-deal market-cap and funding citations do not corroborate the acquisition.
Other verified deals by Hologic
Acquirer program history not already listed as a valuation peer or adjacency row.
| Target | Acquirer | Announced | Value | Sector |
|---|---|---|---|---|
| Gynesonics | Hologic | Sep 15, 2024 | Gynecological Surgery | |
| Endomagnetics | Hologic | May 20, 2024 | Breast Health | |
| Bolder Surgical | Hologic | Oct 14, 2021 | Gynecological Surgery | |
| Biotheranostics | Hologic | Jan 5, 2021 | Breast Health | |
| Acessa Health | Hologic | Aug 25, 2020 | Gynecological Surgery |
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Gen-Probe (Diagnostics). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.